InvestorsHub Logo
Followers 34
Posts 4311
Boards Moderated 0
Alias Born 07/16/2014

Re: slcimmuno post# 93554

Thursday, 03/05/2015 9:24:35 PM

Thursday, March 05, 2015 9:24:35 PM

Post# of 402568
LOL. After reading the first line I was expecting the story to be about the people behind the purchase who forgot to check two things. How secure is the patent protection and what is the competition working on.

Here are a couple of thoughts I had about the article.

One: Maybe it is bad for Cellceutix since Merck and other big pharmas really only care about established revenue streams. In that case no deal till after phase 3.

Two: (And this is nothing but fun speculation). Maybe they don't need Cubists R&D department because they are preparing to focus their efforts on a new generation of antibiotics. " Keller said no decisions have been made on the future of the lexington site as a whole. "We are continuing to look at our footprint in the greater Boston area," she said." Would Beverly, Mass qualify? (Again nothing but fun speculation)

LEGEND OF ABBREVIATIONS
B = Brilacidin, the antibiotic
K = Kevetrin, the oncology drug
P = Prurisol, the psoriasis drug
SAE = Serious Adverse Event
IND = Investigational New Drug


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News